lncRNA MALAT1在弥漫性大B细胞淋巴瘤患者中的表达及其临床意义  

Expression and clinical significance of lncRNA MALAT1 in diffuse large B cell lymphoma

作　　者：黄珊[1] 赵凤 刘迪[1] 谢可[1] 

机构地区：[1]四川省人民医院肿瘤中心,四川成都610072

出　　处：《中国肿瘤生物治疗杂志》2017年第9期1002-1005,共4页Chinese Journal of Cancer Biotherapy

基　　金：四川省卫生和计划生育委员会科技资助项目(No.16PJ475)~~

摘　　要：目的:探讨长链非编码RNA(long non-coding RNA,lnc RNA)肺癌转移相关转录本1(metastasis-associated lung adenocarcinoma transcript 1,MALAT1)在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者血清中的表达水平及其与临床预后的相关性。方法:采集2010年1月至2015年12月期间在四川省人民医院血液科确诊的、临床资料完整的82例DLBCL患者和32例淋巴结反应性增生(reactive lymphoid hyperplasia,RLH)患者的血液标本,用实时荧光定量PCR法检测两组患者血清中lnc RNA MALAT1的表达水平,分析lnc RNA MALAT1表达水平与DLBCL患者临床病理特征及预后的关系。结果:DLBCL患者血清中lnc RNA MALAT1表达水平明显高于RLH患者(7.48±0.27 vs 1.28±0.45,P<0.01)。lnc RNA MALAT1的表达水平与肿瘤大小、临床分期、B症状及国际预后指数(international prognostic index,IPI)相关(均P<0.01)。高表达lnc RNA MALAT1的患者中位无进展生存时间明显短于低表达者[(16.43±2.05)vs(32.01±3.20)个月,P<0.01],lnc RNA MALAT1表达水平与IPI指数是影响DLBCL患者预后的独立因素(P<0.01)。结论:lnc RNA MALAT1在DLBCL患者中的高表达与多项临床病理参数有关,有望成为判断DLBCL患者预后的标志物。Objective：To investigate the expression of lnc RNA MALAT1（long non-coding RNAs,metastasis-associated lung adenocarcinoma transcript 1） in the serum of DLBCL（diffuse large B-cell lymphoma） patients,and to analyze its correlation to clinical prognosis.Methods：The blood samples of 82 DLBCL patients and 32 RLH patients（lymph node reactive hyperplasia）,who were diagnosed at Hematology Department of People＇s Hospital of Sichuan Province from January 2010 to December 2015 with complete clinical data,were collected for this study.lnc RNA MALAT1 expression was detected by Real-time fluorescence quantitative PCR,and the relationship between lnc RNA MALAT1 expression with clinical pathological features and prognosis were analyzed.Results：Compare with RLH patients,lnc RNA MALAT1 expression was significantly increased in DLBCL patients（7.48 ± 0.27 vs1.28 ± 0.45,P〈0.01）.In addition,lnc RNA MALAT1 was significantly correlated with tumor size,clinical stage,B symptoms and international prognostic index（IPI） scores.The median progression free survival time（PFS） of patients with high lnc RNA MALAT1 expression was significantly shorter than those with low expression（[16.43±2.05] months vs [32.01±3.20] months,P〈0.01）.Cox multivariate analyses verified that lnc RNA MALAT1 and IPI scores were independent predictive factors for DLBCL prognosis.Conclusion：The high expression of lnc RNA MALAT1 in DLBCL patients was correlated with multiple clinicopathological parameters.,and it is expected to become a new tumor marker for DLBCL prognosis.

关 键 词：弥漫性大B细胞淋巴瘤 lncRNA MALAT1 临床病理特征 预后 

分 类 号：R733.7[医药卫生—肿瘤] R730.7[医药卫生—临床医学]